Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Salma N Fahmy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology & Toxicology Department, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt. Hauptthemen laut MEDLINE: Carvedilol, ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Interactions, Sofosbuvir. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Sofosbuvir (SOF) is a P-glycoprotein (P-gp) substrate, and carvedilol (CAR) is an inhibitor of P-gp, suggesting that it may affect the oral pharmacokinetics and safety of SOF. The current study investigated the pharmacokinetic interaction of CAR with SOF and its metabolite, GS-331007, and the possible consequent toxicities in rats. To assess the pharmacokinetics of SOF and GS-331007, rats were divided into three groups; all received a single oral dose of SOF preceded with saline (SAL), verapamil (VER) as a standard P-gp inhibitor, or CAR, respectively. The serosal, plasma, and hepatic tissue contents of SOF and GS-331007 were assessed using LC-MS/MS. Renal and hepatic toxicities were assessed using biochemical and histopathological tests. Serosal and plasma concentrations of SOF and GS-331007 were increased in the presence of CAR, suggesting a significant inhibitory effect of CAR on intestinal P-gp. Simultaneously, the pharmacokinetic profile of SOF showed a significant increase in the Cmax, AUC(0-t), AUC (0-∞), t1/2, and a reduction in its apparent oral clearance. While the pharmacokinetic profile of GS-331007 was not significantly affected. However, this notable elevation in drug oral bioavailability was corroborated by a significant alteration in renal functions. Hence, further clinical investigations are recommended to ensure the safety and dosing of CAR/SOF combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology & Toxicology Department, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt.
- Pharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
- Preclinical & Translational Research Center, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Ebtehal El-Demerdash
Zitieren
APA
Fahmy, S. N., Khedr, L. H., Wahdan, S. A., Menze, E. T., Azab, S. S., & El-Demerdash, E. (2024). Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae070
Vancouver
Fahmy SN, Khedr LH, Wahdan SA, Menze ET, Azab SS, El-Demerdash E. Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae070
BibTeX
@article{Fahmy2024,
author = {Fahmy, Salma N and Khedr, Lobna H and Wahdan, Sara A and Menze, Esther T and Azab, Samar S and El-Demerdash, Ebtehal},
title = {Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae070}
}
EUVIMED